RJA
FBIO icon

Raymond James & Associates’s Fortress Biotech FBIO Stock Holding History

Raymond James & Associates’s Portfolio FBIO Stock Details FBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-2,965
Closed -$24.5K – 3835
2023
Q2 		$24.5K Hold
2,965
– – ﹤0.01% 3762
2023
Q1 		$36.5K Hold
2,965
– – ﹤0.01% 3760
2022
Q4 		$29.1K Hold
2,965
– – ﹤0.01% 3762
2022
Q3 		$38K Buy
2,965
+444
+18% +$6.65K ﹤0.01% 3733
2022
Q2 		$32K Hold
2,521
– – ﹤0.01% 3838
2022
Q1 		$51K Hold
2,521
– – ﹤0.01% 3905
2021
Q4 		$95K Hold
2,521
– – ﹤0.01% 3868
2021
Q3 		$122K Hold
2,521
– – ﹤0.01% 3796
2021
Q2 		$135K Hold
2,521
– – ﹤0.01% 3780
2021
Q1 		$133K Hold
2,521
– – ﹤0.01% 3721
2020
Q4 		$120K Sell
2,521
-564
-18% -$24.4K ﹤0.01% 3527
2020
Q3 		$187K Buy
3,085
+564
+22% +$28.7K ﹤0.01% 3243
2020
Q2 		$101K Hold
2,521
– – ﹤0.01% 3282
2020
Q1 		$71K Buy
+2,521
New +$83.7K ﹤0.01% 3275

Other funds holding FBIO

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return
SAM
Shikiar Asset Management New York $396M AUM 41.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Raymond James & Associates's FBIO Position: Q3 2023 in Review

Raymond James & Associates sold out of Fortress Biotech (FBIO) in Q3 2023, closing a stake of 2,965 shares — an estimated $24.5K sold.

Raymond James & Associates first reported a position in FBIO in Q1 2020 and held it in 14 quarters. The position peaked at $187K in Q3 2020. 48 funds tracked by Wall St. Rank hold FBIO as of Q3 2023.

  • Raymond James & Associates reported no remaining Fortress Biotech position as of Q3 2023 after selling out during the quarter.
  • Raymond James & Associates sold 2,965 Fortress Biotech shares in Q3 2023, an estimated $24.5K.
  • Raymond James & Associates first reported a position in Fortress Biotech in Q1 2020 and held it in 14 quarters.
  • Raymond James & Associates's Fortress Biotech position peaked at $187K in Q3 2020.
  • 48 funds tracked by Wall St. Rank held Fortress Biotech as of Q3 2023.

Based on Raymond James & Associates's 13F filing for Q3 2023, filed 24 Oct 2023.